---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-079139"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2023-09-25T23:59:59+00:00"
generated_at: "2026-06-10T09:17:24.989452+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Unicycive receives Nasdaq deficiency notices for market value <$35M and bid price <$1.00

## Summary
- On Sept 19, 2023, Nasdaq notified UNCY its market value of common stock was below $35M minimum for 30 consecutive business days.
- Also on Sept 19, bid price closed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
- Company has 180 calendar days, until March 18, 2024, to regain compliance for both requirements.
- If compliance not regained, common stock may be delisted; Company can appeal to a Hearings Panel.
- Company intends to monitor market value and evaluate options to regain compliance, but no assurance given.

## SEC filing metadata
- accession: 0001213900-23-079139
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2023-09-25T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390023079139/0001213900-23-079139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390023079139/ea185665-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-079139
- JSON: https://secwatch.observer/filing/0001213900-23-079139.json
- Plain text: https://secwatch.observer/filing/0001213900-23-079139.txt

## Key facts
- Listing & Compliance Notices
  Unicycive Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: September 19, 2023, Unicycive Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the market value of the Company’s Common Stock (the “Common Stock”), had closed below the minimum $35 million requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Minimum Market Value Requirement”). The Notice has no immediate effect on the listing or trading of the Common Stock on the N
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023079139/0001213900-23-079139-index.htm
- Listing & Compliance Notices
  Unicycive Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: September 19, 2023, Unicycive Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the market value of the Company’s Common Stock (the “Common Stock”), had closed below the minimum $35 million requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Minimum Market Value Requirement”). The Notice has no immediate effect on the listing or trading of the Common Stock on the N
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023079139/0001213900-23-079139-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.